PapathemeliDGrafeRHildebrandtUet al. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler2016; 22(14): 1888–1890.
2.
JawedSIMyskowskiPLHorwitzSet al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome):part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol2014; 70(2): 205.e1–205.e16, quiz 221–222.
3.
VowelsBRLessinSRCassinMet al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol1994; 103: 669–673.
4.
KapposLO‘ConnorPRadueEet al. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology2015; 84(15): 1582–1591.
5.
LorvikKBBogenBCorthayA.Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood2012; 119(9): 2176–2177.
6.
CohanSGodwinJGaedekeL.Acute lymphoblastic leukemia in a man treated with fingolimod for relapsing multiple sclerosis. J Investig Med High Impact Case Rep2015; 3(1): 2324709615575551.
7.
CohenJKhatriBBarkhofFet al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry2016; 87(5): 468–475.
